Since CD38 could consume NAD+, NAD+ would be elevated by CD38 knock-out and then might stimulate SIRT1 and PARP1 to induce T cell differentiation into Th1 subsets for enhancing the anti-tumor effects [41]. This evidence concerns the gene CD38 and neoplasm.